

Chronic Illnesses II

Myelodysplastic Syndromes

Learning Objectives

1. Distinguish which chemotherapeutic agent is most likely to have contributed to the development of therapy-related myelodysplastic syndromes (tMDS).
2. Compute and apply International Prognostic Scoring System (IPSS) and International Prognostic Scoring System - Revised (IPSS-R) scores for patients with myelodysplastic syndromes (MDS).
3. Devise a plan for initial therapy of the patient with MDS based on IPSS and IPSS-R risk.
4. Design an appropriate regimen for MDS based on likelihood of cure, improvement in overall survival, transfusion independence, and quality of life.
5. Classify adverse effect profiles of therapies for MDS.
6. Evaluate the benefits versus limitations of iron chelation and stem cell transplantation in patients with MDS.

Chronic Myeloid Leukemia

Learning Objectives

1. Analyze available evidence to recommend a first-line therapy for chronic myeloid leukemia (CML).
2. Assess patient response to therapy to determine whether alternative CML treatment options are necessary.
3. Distinguish common adverse events with CML and design appropriate management strategies.
4. Develop a treatment plan for a patient with CML who cannot tolerate first-line treatment.
5. Detect drug-drug interactions common in CML and design a management plan for affected patients.

Pharmacology of New Targeted Therapies

Learning Objectives

1. Evaluate the clinical efficacy and optimal use of targeted therapies in the hematology/oncology patient setting.
2. Assess common adverse effects and monitoring parameters associated with the treatment of newly approved targeted therapies.
3. Account for key drug interactions and appropriate medication management with newly approved targeted therapies in the hematology/oncology patient setting.
4. Develop key patient counseling points on newly approved targeted agents.
5. Evaluate the appropriate dosing of targeted therapies in the setting of impaired organ function or drug-related toxicities.

Oral Chemotherapy

Learning Objectives

1. Distinguish the common adverse drug effects (ADEs) associated with oral chemotherapy agents.
2. Develop strategies to prevent and manage ADEs.
3. Compose counseling points for patients and caregivers regarding the use of oral chemotherapy.
4. Apply best practices to improve safety in the medication use process for oral chemotherapy.
5. Justify the pharmacist's role in improving outcomes for patients receiving oral chemotherapy agents.